SAN FRANCISCO–(BUSINESS WIRE)–Komodo Health right now introduced an settlement with Janssen Research & Development, LLC (Janssen) to speed up scientific improvement utilizing real-world knowledge and AI software program. The collaboration goals to optimize feasibility, web site choice, and affected person recruitment for scientific trials, in the end driving increased throughput for trials and rushing life-saving therapies to sufferers.
As a leader in real-world affected person knowledge, Komodo builds software program that advances scientific improvement by understanding the affected person journey. The strategic partnership at present focuses on software program options that provide real-time visibility into affected person volumes, enhancing the flexibility to determine trial websites, enhance goal recruitment, perceive affected person cohorts earlier than launch, and attain various affected person populations.
“The next generation of clinical trials requires deep and timely insight into the patient journey,” stated Aswin Chandrakantan, MD, chief medical officer, Komodo Health. “Whether targeting a large volume of diverse patients for a prevalent chronic condition or exploring breakthroughs for complex rare diseases, it’s crucial to understand where patients are progressing through the care system in order to improve efficiency in clinical trials.”
The collaboration spans a broad portfolio of therapeutic areas starting from widespread power diseases to ultra-rare illnesses. Areas of collaboration embody infectious illnesses, oncology, vaccines, immunology, cardiovascular, and metabolic illness.
Built on Komodo’s Healthcare MapTM of 325 million U.S. de-identified affected person journeys, the Komodo Health options being deployed embody:
- Prism, to assist feasibility, market sizing, protocol situation planning, and affected person cohort analytics
- Sentinel, for proprietary knowledge integration, analytics, and web site choice
- Pulse, for real-time alerts on encounters between suppliers and potential screening eligible sufferers
Across the business, figuring out the suitable affected person cohorts has traditionally been an arduous and sometimes inefficient course of, significantly in Phase three and four trials. Some studies point out that as much as 80 % of scientific trials fail to satisfy recruitment deadlines. Recruitment and retention challenges can typically result in trial termination, creating moral and monetary penalties and delaying supply of latest medication to affected person populations in want.
About Komodo Health:
Komodo Health believes that smarter, extra modern use of knowledge and analytics is important for lowering illness burden. We apply synthetic intelligence and different superior knowledge science methods to our first-of-its-kind Healthcare Map™, which tracks the distinctive affected person journeys of over 325 million sufferers. We empower a mess of healthcare stakeholders – life science corporations, healthcare payers and suppliers, affected person advocacy teams, and others – to create a cheaper, value-driven healthcare system. For extra info, go to www.komodohealth.com.